Industry Analysis
Infineon’s withdrawal of contested GaN products from the Shanghai show signals a strategic inflection point: Chinese firms like Innoscience are now enforcing IP leverage in home markets. Technically, GaN’s co-optimization of epitaxy and packaging means patent disputes disrupt interface standards across the supply chain. Compliance costs for multinationals will rise as China intensifies localized IP scrutiny—especially critical when advanced nodes (e.g., 3nm/EUV) remain inaccessible. Competitors like Navitas may deepen ties with Chinese foundries to pre-empt legal exposure. Over the next 12–24 months, expect China to consolidate a domestic GaN patent pool, steering industry standards toward local compatibility and fragmenting the global GaN ecosystem into parallel technical regimes.
This page displays AI-generated summaries and metadata for research purposes. Original content belongs to the respective publishers.